The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MDS 2023 | Identifying & monitoring patients with high-risk clonal hematopoiesis
Klaus Metzeler, MD, University of Leipzig Medical Center, Leipzig, Germany, comments on the possibility of identifying patients with clonal hematopoiesis (CH) who are at a high risk of progression to myeloid malignancies, highlighting a recent study that created a CH risk score that allows stratifying patients into low-, intermediate, and high-risk CH. Using this score, it was found that only 1% of patients with CH are at a high risk of progression to myeloid malignancies. Dr Metzeler explains that these patients should be monitored using sequencing methods or artificial intelligence (AI) to enable early intervention. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
